Clinical trial
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer: Phase I Dose Escalation Study
NCT06984562 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer: Phase I Dose Escalation Study
- Lead sponsor
- Fox Chase Cancer Center
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- August 20, 2025
- Completion date
- August 1, 2029
- Enrollment
- 16 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
locally advanced pancreatic ductal adenocarcinoma (pda)